March 07, 2025

Recognise developmental disorders early with AI: Automatically classifying movement patterns in babies

Recognise developmental disorders early with AI: Automatically classifying movement patterns in babies

Using a new combination of three sensors and artificial intelligence, researchers at Heidelberg Medical Faculty of Heidelberg University and Heidelberg University Hospital are recognising patterns in babies’ movements that show whether their nervous system is developing healthily.

The way an infant moves spontaneously in the first few months of life can indicate whether its nervous system has a disorder and predict whether the baby will later develop cerebral palsy, for example. This has been the result of research over the last few decades. Until now, these age-specific spontaneous movement patterns – researchers refer to them as ‘general movements’ – have been clinically analysed using video data. Prof Dr Dr Peter Marschik from the Heidelberg Medical Faculty at Heidelberg University and his team have now presented the first combination method with which they can automatically classify early childhood movements. Marschik heads the Systemic Ethology and Developmental Science research unit at the Department of Child and Adolescent Psychiatry at Heidelberg University Hospital (UKHD). In his study with babies aged from four weeks after their due date, he and his colleagues were able to show that the ‘Sensor Fusion Model’ can automatically detect neurological movement disorders at an early stage, which should support diagnostics in the future. The automatic detection of abnormal movement patterns in babies could also contribute to a better understanding of the early development of the nervous system.

Better treatment for neurological disorders recognised early

Early detection of neurological disorders can be decisive for the future life of children. This is because the nervous system continues to develop rapidly after birth, and external influences can promote or impair this. Studies in recent years have shown that early interventions such as physiotherapy can alleviate later symptoms in children with cerebral palsy, which can lead to movement disorders and spasticity (muscle stiffness). Cerebral palsy affects one to four newborns in every 1000 births worldwide. The ‘General Movement Assessment (GMA)’ is one method used to recognise it at an early stage. This involves doctors analysing the child’s movements. Ideally, the GMA is clinically combined with further neurological examinations and MRI imaging. As these methods are not equally accessible everywhere, scientists around the world are looking to introduce automated analyses using artificial intelligence for GMA as a screening tool.

SEE – Sensor Fusion Model precisely recognises movement abnormalities

In the current study, the scientists examined over 50 children at two-week and later weekly intervals. In their sensor fusion model, Peter Marschik and his team combined visual sensor technology with the measurement of pressure distribution using highly sensitive pressure mats and inertial sensor technology, which is used to measure spatial movement. The joint evaluation of all three data sources using artificial intelligence resulted in a significantly higher accuracy in the classification of paediatric movement disorders compared to the video-based sensor alone. ‘The Sensor Fusion model reliably distinguishes between typical and deviant movement patterns and can therefore show us whether the child’s nervous system is doing well and developing appropriately for their age,’ summarises Peter Marschik. The model could therefore contribute to an earlier diagnosis of developmental disorders. In the field of basic research, the automatic classification of early movement patterns could also help to better understand the development of neurodevelopmental disorders, such as autism spectrum disorders. 

The research work of Peter Marschik’s team is interdisciplinary and is carried out in collaboration with universities and medical institutions in Göttingen, Graz, Berlin, Los Angeles and Stockholm.

Literature:
Kulvicius T, Zhang D, Poustka L, Bölte S, Jahn L, Flügge S, Kraft M, Zweckstetter M, Nielsen-Saines K, Wörgötter, F, Marschik PB. Deep learning empowered sensor fusion boosts infant movement classification. Communications Medicine. 2025;5:16. doi:10.1038/s43856-024-00701-w


The analysis using artificial intelligence resulted in a significantly higher accuracy in the classification of paediatric movement disorders compared to the video-based sensor alone. Photo: University Medical Centre Göttingen
The analysis using artificial intelligence resulted in a significantly higher accuracy in the classification of paediatric movement disorders compared to the video-based sensor alone. Photo: University Medical Centre Göttingen

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp